Clozapine induced weight gain: A pharmacogenetic study
Research type
Research Study
Full title
Clozapine induced weight gain: A pharmacogenetic study
IRAS ID
185487
Contact name
Victor M Aziz
Contact email
Sponsor organisation
Cwm Taf UHB
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Clozapine is prescribed to patients with psychosis in whom other treatments have not worked. Research has shown, however, that clozapine may be associated with weight gain and abnormal blood sugar levels in some patients. There is strong evidence to suggest that genetic variation between individuals plays an important role in the development of these side effects in response to the medication. Our research aims to evaluate the effects of two genes and the blood level of clozapine on side-effects such as weight changes and blood sugar levels in patients receiving clozapine treatment. From out-patient clinics in Cwm Taf UHB, we aim to recruit 160 patients who are taking clozapine; collect information/ measurements from recruits relating to size/ weight/ BMI, risk of diabetes and blood samples to measure markers of blood sugar, fat/lipids, clozapine and its breakdown products, blood cells and variants of two specific genes. From this information we will be particularly interested to understand if there is any association between the variation in these two genes with weight gain or changes in blood sugar, in patients taking clozapine.
REC name
Wales REC 6
REC reference
16/WA/0369
Date of REC Opinion
2 Feb 2017
REC opinion
Further Information Favourable Opinion